Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia

Inclusion Criteria: * 19 \~ 80 years old * High risk patient to Coronary Heart Disease * At Visit 1(Screening) 1. Treated with Rosuvastatin 10mg monotherapy 4weeks prior to this study 2. 110 mg/dl ≥ LDL-C, 200 mg/dl ≤ TG ≤ 500 mg/dl * At Visit 2 (Baseline), 110 mg/dl ≥ LDL-C, 200 mg/dl ≤ TG ≤ 500 mg/dl Exclusion Criteria: * AST or ALT \> 2X ULN * Patients with uncontrolled hyperthyroidism (TSH\>1.5X ULN) * Patients with uncontrolled diabetes (HbA1c ≥ 9%) * Patients with uncontrolled hypertension(SBP\>160mmHg or DBP\>95mmHg) * Patients with congestive heart failure(NYHA class III\~IV) or uncontrolled arrhythmia within 6 months * Patients treated with any investigational drugs within 3 months at the time consents are obtained * Not eligible to participate for the study at the discretion of investigator